4.2 Article

Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain

Journal

PHARMACOGENOMICS
Volume 12, Issue 5, Pages 727-734

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/PGS.11.16

Keywords

5-HT2C; antipsychotic; regulatory polymorphism; weight gain

Funding

  1. MRC
  2. Grants-in-Aid for Scientific Research [23659295] Funding Source: KAKEN

Ask authors/readers for more resources

Background: Genetic variation in the promoter region of HTR2C encoding for the 5-HT2C receptor is associated with antipsychotic-induced weight gain. Several studies have investigated the regulatory potential of associated variants using gene-reporter systems. Establishing associated polymorphisms as causal variants may aid in the identification of the molecular mechanisms of phenotypic variation. Aims & methods: To this end we examined the binding of nuclear factors from rat hypothalamus to two polymorphisms in HTR2C, rs3813929 (-759C/T) and rs518147 (-697C/G) using electromobility shift assays. For rs518147, allele-specific RNA folding was also investigated. Results: Both polymorphisms bound nuclear factors, identifying the sequence fragments as regulatory elements. Importantly, rs3813929 (-759C/T) altered DNA-protein interactions with the weight gain-resistant allele abolishing the formation of two complexes. The formation of allele-specific RNA loops was also observed for rs518147. Conclusion: These data establish rs3813929 (-759C/T) as a functional polymorphism and suggest disruption of DNA-protein interactions as a mechanism by which HTR2C expression is perturbed leading to an influence on antipsychotic-induced weight gain.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Clinical Neurology

Schizophrenia, Depressive Symptoms, and Antipsychotic Drug Treatment

Gavin P. Reynolds, Olga O. McGowan

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2021)

Article Genetics & Heredity

Changes of BDNF exon IV DNA methylation are associated with methamphetamine dependence

Sri-Arun Iamjan, Samur Thanoi, Paritat Watiktinkorn, Helene Fachim, Caroline F. Dalton, Sutisa Nudmamud-Thanoi, Gavin P. Reynolds

Summary: The study investigated the effects of methamphetamine on DNA methylation of BDNF in humans and rats, finding increased methylation in patients and rats with METH exposure. These changes may affect BDNF expression and contribute to the neurotoxic effects of METH.

EPIGENOMICS (2021)

Article Genetics & Heredity

The relationship of childhood trauma and DNA methylation of NMDA receptor genes in first-episode schizophrenia

Camila M. Loureiro, Helene A. Fachim, Fabiana Corsi-Zuelli, Rosana Shuhama, Paulo R. Menezes, Caroline F. Dalton, Cristina M. Del-Ben, Gavin P. Reynolds, Paulo Louzada-Junior

Summary: The study found that childhood trauma may influence DNA methylation in individuals with a predisposition to psychosis, but not in those with frank schizophrenia or controls.

EPIGENOMICS (2021)

Letter Clinical Neurology

The Etiology of Metabolic Disturbances in Schizophrenia: Drugs, Genes, and Environment

Gavin P. Reynolds

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2021)

Editorial Material Clinical Neurology

High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?

Gavin P. Reynolds

Summary: Guidelines for schizophrenia treatment emphasize the importance of dosage and mechanism of action, particularly highlighting the benefits of partial agonist drugs in reducing side effects while maintaining efficacy.

JOURNAL OF PSYCHOPHARMACOLOGY (2021)

Article Clinical Neurology

Early-life stress effects on BDNF DNA methylation in first-episode psychosis and in rats reared in isolation

Helene A. Fachim, Fabiana Corsi-Zuelli, Camila M. Loureiro, Sri-arun Iamjan, Rosana Shuhama, Samia Joca, Paulo Rossi Menezes, Adrian Heald, Paulo Louzada-Junior, Caroline F. Dalton, Cristina Marta Del-Ben, Gavin P. Reynolds

Summary: The study suggests that childhood maltreatment may result in increased BDNF methylation, providing a mechanism underlying the association between early-life stress and psychosis.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2021)

Editorial Material Genetics & Heredity

Early life trauma, DNA methylation and mental illness

Gavin P. Reynolds

EPIGENOMICS (2021)

Meeting Abstract Clinical Neurology

Parvalbumin (PVALB) promoter dna methylation association with early-life trauma in first episode psychosis patients

H. Fachim, C. Loureiro, F. Corsi-Zuelli, P. Rossi-Menezes, P. Louzada-, C. Dalton, A. Heald, C. M. Del-Ben, G. Reynolds

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2021)

Review Clinical Neurology

The neurochemical pathology of schizophrenia: post-mortem studies from dopamine to parvalbumin

Gavin P. Reynolds

Summary: Research in Peter Riederer's lab in Vienna in the late 1970s stemmed from a strong tradition in post-mortem neurochemical studies, acknowledging the value of post-mortem brain tissue in understanding pharmacological mechanisms of neuropsychiatric treatments. Investigating dopamine, D2 receptors, and GABAergic neurons led to the discovery of deficits associated with schizophrenia. Subsequent research on DNA methylation of the parvalbumin gene aims to further understand these findings in psychotic illness and its animal models.

JOURNAL OF NEURAL TRANSMISSION (2022)

Article Clinical Neurology

Subchronic PCP effects on DNA methylation and protein expression of NMDA receptor subunit genes in the prefrontal cortex and hippocampus of female rats

Camila M. Loureiro, Helene A. Fachim, Michael K. Harte, Caroline F. Dalton, Gavin P. Reynolds

Summary: This study investigated the DNA methylation and protein expression changes in NMDAR subunits in the prefrontal cortex and hippocampus of rats after subchronic PCP administration. The results showed hypermethylation of Grin1 and Grin2b promoters and reduction in NR1 protein levels. These alterations may contribute to the pathogenesis of schizophrenia.

JOURNAL OF PSYCHOPHARMACOLOGY (2022)

Article Immunology

Nicotinamide reverses deficits in puberty-born neurons and cognitive function after maternal separation

Keke Hao, Huiling Wang, Yuejin Zhang, Xinhui Xie, Huan Huang, Cheng Chen, Shilin Xu, Rui Xu, Chang Shu, Zhongchun Liu, Yuan Zhou, Gavin P. Reynolds, Gaohua Wang

Summary: Early life stress may lead to schizophrenia-like phenotypes and persistent hippocampal abnormalities. Nicotinamide may be a safe and effective treatment in adolescence to restore normal hippocampal function and prevent or ameliorate schizophrenia-like behavior.

JOURNAL OF NEUROINFLAMMATION (2022)

Review Psychiatry

Dopamine partial agonists: a discrete class of antipsychotics

David Taylor, Ramalingam Chithiramohan, Jasdev Grewal, Avirup Gupta, Lars Hansen, Gavin P. Reynolds, Sofia Pappa

Summary: There are three marketed dopamine D2 partial agonists worldwide: aripiprazole, brexpiprazole, and cariprazine. These drugs have similar pharmacological properties and clinical effects, including being effective antipsychotics with antimanic and antidepressant activity. They are well tolerated with minimal side effects and have a low risk of increased prolactin, weight gain, and tardive dyskinesia.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2023)

Article Psychiatry

Partial agonists of dopamine receptors: clinical effects and dopamine receptor interactions in combining aripiprazole with a full antagonist in treating psychosis

John Cookson, Jonathan Pimm, Gavin Reynolds

Summary: This study examines the effects of combining partial agonists and full antagonists in the treatment of psychosis and analyzes the impact of the dopamine hypothesis on treatment outcomes. The combinations considered include aripiprazole with amisulpride, with risperidone in people with hyperprolactinaemia, and with olanzapine to mitigate weight gain. The study discusses the potential worsening of symptoms by adding or switching to a partial agonist and explores the adverse interaction with a full antagonist, such as haloperidol, during a subsequent relapse to control severe agitation.

BJPSYCH ADVANCES (2023)

Article Psychology, Clinical

Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial

Yamin Zhang, Qiang Wang, Gavin P. Reynolds, Weihua Yue, Wei Deng, Hao Yan, Liwen Tan, Chuanyue Wang, Guigang Yang, Tianlan Lu, Lifang Wang, Fuquan Zhang, Jianli Yang, Keqing Li, Luxian Lv, Qingrong Tan, Yinfei Li, Hua Yu, Hongyan Zhang, Xin Ma, Fude Yang, Lingjiang Li, Qi Chen, Wei Wei, Liansheng Zhao, Huiyao Wang, Xiaojing Li, Wanjun Guo, Xun Hu, Yang Tian, Hongyan Ren, Xiaohong Ma, Jeremy Coid, Dai Zhang, Tao Li

JOURNAL OF CLINICAL PSYCHIATRY (2020)

No Data Available